-

Baxter Announces Updates to Its Board of Directors

  • Addition of Stephen H. Rusckowski complements and expands current board expertise with deep healthcare industry and public company board experience
  • Michael Mahoney to resign after nearly eight years of board service

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Stephen (Steve) H. Rusckowski, former chairman, president and chief executive officer of Quest Diagnostics, Inc., to its board of directors. Effective today, Mr. Rusckowski serves on Baxter’s Compensation and Human Capital, and Quality, Compliance and Technology Committees. In addition, the company has announced that Michael (Mike) Mahoney will be resigning from the board effective Sept. 13, 2023, following nearly eight years of service.

“We are pleased to welcome Steve to Baxter’s board,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “His exemplary operational expertise, track record as a transformational leader, and distinguished career as a strategic operational executive will enhance our current board membership. I’m confident Steve’s patient-centric approach will further advance our Mission to Save and Sustain Lives.”

Added Almeida, “I also want to thank Mike for his many contributions to the Baxter board over his eight-year tenure. His extensive insight into the medical device industry and deep leadership experience have helped guide Baxter’s ongoing transformation, including our current strategic actions to drive greater growth, innovation and performance.”

About Steve Rusckowski

Mr. Rusckowski most recently served as chairman, president and chief executive officer of Quest Diagnostics, Inc. Prior to joining Quest Diagnostics, he was CEO of Philips Healthcare, and earlier in his career held roles of increasing responsibility at Hewlett-Packard Company and Procter & Gamble Company. Mr. Rusckowski currently serves as a director of Tenet Healthcare Corporation and Qiagen Inc. and previously served as a member of the boards of directors of Xerox Holdings Corporation, Covidien plc and MedQuist, Inc. He earned a bachelor’s degree in mechanical engineering from Worcester Polytechnic Institute and a Master of Management Science from the Massachusetts Institute of Technology’s Sloan School of Management.

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Baxter is a registered trademark of Baxter International Inc.

Contacts

Media Contact
Stacey Eisen, (224) 948-5353
media@baxter.com

Investor Contact
Clare Trachtman, (224) 948-3020

Baxter International Inc.

NYSE:BAX

Release Versions

Contacts

Media Contact
Stacey Eisen, (224) 948-5353
media@baxter.com

Investor Contact
Clare Trachtman, (224) 948-3020

More News From Baxter International Inc.

Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fix...

Baxter Announces Early Tender Results for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the early tender results for the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The tender offers are being made pursuant to the terms and conditions set forth in the offer to purchase, dated Nov. 19, 2025, as amended by the Company’s press release dated Nov. 19, 2025 (as it may be further amended or supplemented from time to time...

Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the “2027 Notes”) that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the “2027 Notes Tender Offer”) from $300 million to $600 million, on the terms and subject to the conditions set forth in...
Back to Newsroom